ウイルスベクター市場：タイプ、疾患、用途、エンドユーザー別-2025-2030年の世界予測

ウイルスベクター市場は、2023年に16億6,000万米ドルと評価され、2024年には18億8,000万米ドルに達すると予測され、CAGR 14.09%で成長し、2030年には41億8,000万米ドルになると予測されています。

360iResearchの市場調査アナリストとして、ウイルスベクター市場を調査することで、遺伝子治療、ワクチン開発、細胞内に遺伝物質を送達する分子生物学で使用される不可欠なツールとして、その範囲が明らかになります。ウイルスベクターの必要性は、効率的な遺伝子導入を促進する能力により、遺伝性疾患、感染症、がんの治療を含む重要なヘルスケアソリューションへの応用に起因しています。最終用途の範囲には、遺伝子研究の推進と新規治療薬の開発に重点を置く製薬・バイオテクノロジー企業、研究機関、臨床研究所が主に含まれます。主な成長促進要因としては、研究開発投資の増加、遺伝子治療技術の進歩、革新的治療を必要とする慢性疾患の有病率の上昇などが挙げられます。さらに、ベクター設計と送達システムにおける技術的進歩は、遺伝子治療の可能性を最大限に活用するために不可欠な安全性と効率性を向上させる潜在的な機会を開いています。とはいえ、市場の成長は、高い製造コスト、複雑な規制の枠組み、患者における潜在的な免疫原性といった課題に直面しています。技術革新は、ベクター送達メカニズムの改善、副作用の最小化、スケーラブルな製造プロセスの開発に焦点を当てるべきです。さらに、費用対効果が高く、的を絞ったベクターソリューションの開発を推進するために、学術研究機関や臨床研究機関との協力が推奨されます。また、非ウイルス性送達方法のさらなる探求は、現在のウイルスベクターがもたらす限界を埋め、より安全で効率的な治療への道を開くかもしれないです。市場の競争は激しく、絶え間ない技術革新と提携がその情勢を形成しているため、戦略的研究開発投資と機敏な市場参入戦略の必要性が強調されています。急成長するビジネスチャンスを生かすため、利害関係者は高度なアナリティクスと機械学習ツールを研究活動に統合し、治療開発の精度を高め、ウイルスベクター・アプリケーションの拡張性と採用を強化することに注力すべきです。

市場力学：急速に進化するウイルスベクター市場の主要市場インサイトを公開

ウイルスベクター市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 様々な感染症やウイルスに対するワクチン製造の増加
  • 対象疾患や疾病の有病率の増加
  • 細胞・遺伝子治療に対する政府の取り組み
• 市場抑制要因
  • 遺伝子・細胞治療費の高騰
• 市場機会
  • 希少疾患治療における継続的な研究開発
  • 大手受託開発・製造企業による投資
• 市場の課題
  • 挿入突然変異誘発と免疫反応のリスク

ポーターの5つの力：ウイルスベクター市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：ウイルスベクター市場における外部からの影響の把握

外部マクロ環境要因は、ウイルスベクター市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析ウイルスベクター市場における競合情勢の把握

ウイルスベクター市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスウイルスベクター市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、ウイルスベクター市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨ウイルスベクター市場における成功への道筋を描く

ウイルスベクター市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • さまざまな感染症やウイルスに対するワクチン生産の増加
    • 対象となる病気や疾患の蔓延の増加
    • 細胞・遺伝子治療に関する政府の取り組み
  • 抑制要因
    • 遺伝子・細胞治療の高額な費用
  • 機会
    • 希少疾患治療における継続的な研究開発
    • 大規模な開発・製造受託組織による投資
  • 課題
    • 挿入変異と免疫反応のリスク
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 ウイルスベクター市場：タイプ別

• アデノ随伴ウイルスベクター
• アデノウイルスベクター
• レトロウイルスベクター

第7章 ウイルスベクター市場：疾患別

• がん
• 遺伝性疾患
• 感染症

第8章 ウイルスベクター市場：用途別

• 遺伝子治療
• ワクチン学

第9章 ウイルスベクター市場：エンドユーザー別

• 製薬・バイオ医薬品企業
• 調査機関

第10章 南北アメリカのウイルスベクター市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域のウイルスベクター市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカのウイルスベクター市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• ABL Inc.
• Batavia Biosciences B.V.
• Bio-Rad Laboratories, Inc.
• BioNTech IMFS GmbH
• Biovian Oy
• Cevec Pharmaceuticals GmbH
• Creative Biogene
• FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
• GeneOne Life Science, Inc.
• Lonza Group Ltd.
• Merck KGaA
• Miltenyi Biotec B.V. & Co. KG
• Sirion-Biotech GmbH
• Spark Therapeutics, Inc. by F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.

LIST OF FIGURES

• FIGURE 1. VIRAL VECTORS MARKET RESEARCH PROCESS
• FIGURE 2. VIRAL VECTORS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL VIRAL VECTORS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL VIRAL VECTORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL VIRAL VECTORS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL VIRAL VECTORS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL VIRAL VECTORS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL VIRAL VECTORS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL VIRAL VECTORS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL VIRAL VECTORS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES VIRAL VECTORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES VIRAL VECTORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. VIRAL VECTORS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. VIRAL VECTORS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. VIRAL VECTORS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL VIRAL VECTORS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL VIRAL VECTORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. VIRAL VECTORS MARKET DYNAMICS
• TABLE 7. GLOBAL VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENO-ASSOCIATED VIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENOVIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL VIRAL VECTORS MARKET SIZE, BY RETROVIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL VIRAL VECTORS MARKET SIZE, BY CANCERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL VIRAL VECTORS MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL VIRAL VECTORS MARKET SIZE, BY VACCINOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 34. CANADA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. CANADA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 36. CANADA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 37. CANADA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES VIRAL VECTORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 52. AUSTRALIA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 56. CHINA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 57. CHINA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 58. CHINA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. CHINA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 60. INDIA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. INDIA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 62. INDIA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 63. INDIA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 64. INDONESIA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 65. INDONESIA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 68. JAPAN VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 69. JAPAN VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 72. MALAYSIA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. MALAYSIA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 76. PHILIPPINES VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. PHILIPPINES VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 80. SINGAPORE VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 81. SINGAPORE VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 84. SOUTH KOREA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 88. TAIWAN VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. TAIWAN VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 92. THAILAND VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 93. THAILAND VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 96. VIETNAM VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. VIETNAM VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 100. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 105. DENMARK VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 106. DENMARK VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 109. EGYPT VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. EGYPT VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 113. FINLAND VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 114. FINLAND VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 117. FRANCE VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 118. FRANCE VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 121. GERMANY VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. GERMANY VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 125. ISRAEL VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 126. ISRAEL VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 129. ITALY VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 130. ITALY VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 131. ITALY VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 132. ITALY VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 133. NETHERLANDS VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. NETHERLANDS VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 137. NIGERIA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. NIGERIA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 141. NORWAY VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 142. NORWAY VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 145. POLAND VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 146. POLAND VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 147. POLAND VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 148. POLAND VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 149. QATAR VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 150. QATAR VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 151. QATAR VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 152. QATAR VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 153. RUSSIA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 154. RUSSIA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 157. SAUDI ARABIA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 158. SAUDI ARABIA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 161. SOUTH AFRICA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 162. SOUTH AFRICA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 165. SPAIN VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 166. SPAIN VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 169. SWEDEN VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 170. SWEDEN VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 173. SWITZERLAND VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 174. SWITZERLAND VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 177. TURKEY VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 178. TURKEY VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 181. UNITED ARAB EMIRATES VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 182. UNITED ARAB EMIRATES VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 185. UNITED KINGDOM VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 186. UNITED KINGDOM VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 189. VIRAL VECTORS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 190. VIRAL VECTORS MARKET, FPNV POSITIONING MATRIX, 2023

The Viral Vectors Market was valued at USD 1.66 billion in 2023, expected to reach USD 1.88 billion in 2024, and is projected to grow at a CAGR of 14.09%, to USD 4.18 billion by 2030.

As a Market Research Analyst at 360iResearch, the exploration of the viral vectors market uncovers its scope as integral tools used in gene therapy, vaccine development, and molecular biology to deliver genetic material into cells. The necessity of viral vectors stems from their application in critical healthcare solutions, including the treatment of genetic disorders, infectious diseases, and cancers, owing to their ability to facilitate efficient gene transfer. End-use scope primarily encompasses pharmaceutical and biotechnology companies, research institutions, and clinical laboratories focused on advancing genetic research and developing novel therapeutics. Key growth drivers include increasing research and development investments, advancements in gene therapy techniques, and rising prevalence of chronic diseases demanding innovative treatments. Furthermore, technological advancements in vector design and delivery systems open potential opportunities for enhancement in safety and efficiency, vital for harnessing the full potential of gene therapies. Nevertheless, market growth faces challenges such as high production costs, complex regulatory frameworks, and potential immunogenicity in patients. Innovations should focus on improving vector delivery mechanisms, minimizing adverse effects, and developing scalable manufacturing processes. Moreover, collaborations with academic and clinical research institutions are recommended to drive the development of cost-effective and targeted vector solutions. Further exploration into non-viral delivery methods might also bridge the limitations posed by current viral vectors, paving the way for safer and more efficient therapies. The nature of the market is intensely competitive, with continuous innovations and partnerships shaping its landscape, thus emphasizing the need for strategic R&D investments and agile market entry strategies. To capitalize on the burgeoning opportunities, stakeholders should focus on integrating advanced analytics and machine learning tools in their research efforts, enabling precision in therapeutic development and enhancing the scalability and adoption of viral vector applications.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Viral Vectors Market

The Viral Vectors Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing vaccine production for various infections and viruses
  • Growing prevalence of target ailments and diseases
  • Government initiatives for cell and gene therapy treatments
• Market Restraints
  • High cost of gene & cell therapy treatments
• Market Opportunities
  • Ongoing research and development in rare disease treatments
  • Investments by large contract development and manufacturing organizations
• Market Challenges
  • Risk of insertional mutagenesis and immune response

Porter's Five Forces: A Strategic Tool for Navigating the Viral Vectors Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Viral Vectors Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Viral Vectors Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Viral Vectors Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Viral Vectors Market

A detailed market share analysis in the Viral Vectors Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Viral Vectors Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Viral Vectors Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Viral Vectors Market

A strategic analysis of the Viral Vectors Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Viral Vectors Market, highlighting leading vendors and their innovative profiles. These include ABL Inc., Batavia Biosciences B.V., Bio-Rad Laboratories, Inc., BioNTech IMFS GmbH, Biovian Oy, Cevec Pharmaceuticals GmbH, Creative Biogene, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., GeneOne Life Science, Inc., Lonza Group Ltd., Merck KGaA, Miltenyi Biotec B.V. & Co. KG, Sirion-Biotech GmbH, Spark Therapeutics, Inc. by F. Hoffmann-La Roche Ltd., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Viral Vectors Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Adeno-associated Viral Vectors, Adenoviral Vectors, and Retroviral Vectors.
• Based on Disease, market is studied across Cancers, Genetic Disorders, and Infectious Diseases.
• Based on Application, market is studied across Gene Therapy and Vaccinology.
• Based on End User, market is studied across Pharmaceutical & Biopharmaceutical Companies and Research Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing vaccine production for various infections and viruses
    • 5.1.1.2. Growing prevalence of target ailments and diseases
    • 5.1.1.3. Government initiatives for cell and gene therapy treatments
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of gene & cell therapy treatments
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing research and development in rare disease treatments
    • 5.1.3.2. Investments by large contract development and manufacturing organizations
  • 5.1.4. Challenges
    • 5.1.4.1. Risk of insertional mutagenesis and immune response
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Viral Vectors Market, by Type

• 6.1. Introduction
• 6.2. Adeno-associated Viral Vectors
• 6.3. Adenoviral Vectors
• 6.4. Retroviral Vectors

7. Viral Vectors Market, by Disease

• 7.1. Introduction
• 7.2. Cancers
• 7.3. Genetic Disorders
• 7.4. Infectious Diseases

8. Viral Vectors Market, by Application

• 8.1. Introduction
• 8.2. Gene Therapy
• 8.3. Vaccinology

9. Viral Vectors Market, by End User

• 9.1. Introduction
• 9.2. Pharmaceutical & Biopharmaceutical Companies
• 9.3. Research Institutes

10. Americas Viral Vectors Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Viral Vectors Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Viral Vectors Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. ABL Inc.
• 2. Batavia Biosciences B.V.
• 3. Bio-Rad Laboratories, Inc.
• 4. BioNTech IMFS GmbH
• 5. Biovian Oy
• 6. Cevec Pharmaceuticals GmbH
• 7. Creative Biogene
• 8. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
• 9. GeneOne Life Science, Inc.
• 10. Lonza Group Ltd.
• 11. Merck KGaA
• 12. Miltenyi Biotec B.V. & Co. KG
• 13. Sirion-Biotech GmbH
• 14. Spark Therapeutics, Inc. by F. Hoffmann-La Roche Ltd.
• 15. Thermo Fisher Scientific Inc.